Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.

Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.

Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.

The company will lower the US list price of Levemir, NovoLog and certain other branded insulins by 65-75% and will also lower some unbranded insulin prices effective January 2024. Tresiba is not included.

WW International’s decision to move into pharmaceutical weight management could build commercial momentum for Novo Nordisk’s Wegovy and Lilly’s Mounjaro.

Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.